Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine
- 11 February 2005
- Vol. 330 (7490) , 503
- https://doi.org/10.1136/bmj.38356.655266.82
Abstract
Objective To investigate the efficacy of hypericum extract WS 5570 (St John's wort) compared with paroxetine in patients with moderate to severe major depression. Design Randomised double blind, double dummy, reference controlled, multicentre non-inferiority trial. Setting 21 psychiatric primary care practices in Germany. Participants 251 adult outpatients with acute major depression with total score ≥ 22 on the 17 item Hamilton depression scale. Interventions 900 mg/day hypericum extract WS 5570 three times a day or 20 mg paroxetine once a day for six weeks. In initial non-responders doses were increased to 1800 mg/day hypericum or 40 mg/day paroxetine after two weeks. Main outcome measures Change in score on Hamilton depression scale from baseline to day 42 (primary outcome). Secondary measures were change in scores on Montgomery-Åsberg depression rating scale, clinical global impressions, and Beck depression inventory. Results The Hamilton depression total score decreased by mean 14.4 (SD 8.8) points, corresponding to 56.6% (SD 34.3%) of the baseline value, in the hypericum group and by 11.4 (SD 8.6) points (44.8% (SD 33.5%) of baseline value) in the paroxetine group (intention to treat analysis; similar results were observed in the per protocol analysis). The intention to treat analysis (lower one sided 97.5% confidence limit 1.5 points for the difference hypericum minus paroxetine) and the per protocol analysis (lower confidence limit 0.7 points) showed non-inferiority of hypericum and statistical superiority over paroxetine. The lower limits in both cases exceeded the pre-specified non-inferiority margin of −2.5 points and the superiority margin of 0. The incidence of adverse events was 0.035 and 0.060 events per day of exposure for hypericum and paroxetine, respectively. Conclusions In the treatment of moderate to severe major depression, hypericum extract WS 5570 is at least as effective as paroxetine and is better tolerated.Keywords
This publication has 18 references indexed in Scilit:
- St John's wort for major depressionCochrane Database of Systematic Reviews, 2008
- Drug interactions with St. John’s Wort (Hypericum perforatum): a review of the clinical evidenceInt. Journal of Clinical Pharmacology and Therapeutics, 2004
- Efficacy of St. John’s Wort Extract WS 5570 in Major Depression: A Double-Blind, Placebo-Controlled TrialAmerican Journal of Psychiatry, 2002
- Effect of Hypericum perforatum (St John's Wort) in Major Depressive DisorderJAMA, 2002
- Incidence and clinical relevance of the interactions and side effects of Hypericum preparations.2001
- Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks Commentary: Has hypericum found its place in antidepressant treatment?BMJ, 1999
- The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.1998
- LI 160, an Extract of St. John's Wort, Versus Amitriptyline in Mildly to Moderately Depressed Outpatients - A Controlled 6-Week Clinical TrialPharmacopsychiatry, 1997
- The classification of depression.Published by Wiley ,1983
- CONFIDENCE LIMITS ON THE RATIO OF TWO POISSON VARIABLESAmerican Journal of Epidemiology, 1974